Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
asthma
Biotech
Sanofi BTK inhibitor readout in chronic hives sets up ph. 3 push
Sanofi focused on the results for the three-times-a-day regimen, which produced a “significant” reduction in weekly itch score at Week 12.
James Waldron
Feb 26, 2024 10:35am
Jasper eyes next indication for hive drug, thanks to mouse data
Feb 26, 2024 6:00am
Rapt faces clinical hold after liver failure in immunology trial
Feb 20, 2024 10:42am
GSK pays $1B to challenge Amgen, AstraZeneca for asthma market
Jan 9, 2024 6:00am
Connecting the dots: Asthma asset aces phase 2b trial
Dec 12, 2023 11:00am
Triveni raises $92M for I&I pipeline after Modify, Amagma merger
Oct 26, 2023 11:27am